Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now
Close

Gelesis Holdings Inc (GLSHQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.01 0.00    0.00%
16/01 - Closed. Currency in USD ( Disclaimer )
After Hours
0.02
+0.01
+100.00%
15:49:22 - Delayed Data
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.01 - 0.01
Gelesis Holdings 0.01 0.00 0.00%

Gelesis Holdings Inc Company Profile

 
Get an in-depth profile of Gelesis Holdings Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

93

Equity Type

ORD

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Contact Information

Address 501 Boylston Street Suite 6102
Boston, 02116
United States
Phone 617 456 4718
Fax -

Top Executives

Name Age Since Title
Louis J. Aronne 66 2015 Member of Scientific Advisory Board
James Hill - - Member of Scientific Advisory Board
Allan Geliebter - - Member of Scientific Advisory Board
Hassan M. Heshmati 70 2020 Member of Scientific Advisory Board
Angelo Tremblay - 2015 Member of Scientific Advisory Board
Caroline M. Apovian - - Member of Scientific Advisory Board
Alison Perry Bauerlein 41 2022 Independent Director
Lee M. Kaplan - - Member of Scientific Advisory Board
Arne V. Astrup - - Member of Scientific Advisory Board
Ken Fujioka - 2015 Member of Scientific Advisory Board
Bennett M. Shapiro 82 - Member of Scientific Advisory Board
Clayton Christopher 48 - Independent Director
Jane Larsen Wildman 60 2021 Independent Director
Paul R. Fonteyne 62 2022 Independent Director
Kathryn E. Cavanaugh 48 2022 Independent Director
Yishai Zohar 60 2022 Founder, President, CEO, Chief Compl. Officer, Secretary, Treasurer, Interim PFO and PAO & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GLSHQ Comments

Write your thoughts about Gelesis Holdings Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Matias Lagos
Matias Lagos Feb 10, 2023 1:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pronto AC
She Tried It
She Tried It Jun 14, 2022 11:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anybody buying in now that GLS is down from $5 something 6/6/22 to $1.80 6/14/22... even with them blowing through operating cash but heavily advertising Plenity?
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Jan 31, 2022 6:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Added $5,10 short squeeze will be epic.. tomorrow🚀🚀🚀🚀🚀🚀
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email